Better Therapeutics, Inc. (NASDAQ: BTTX) (the “Company”) announced today that the Company is terminating its employees and will explore strategic...
One million prescriptions for AspyreRx will be offered to patients in underserved communities disproportionately affected by type 2 diabetes...
Company to host sponsored education session on Saturday, March 09, 2024; Expanding access to a high quality and effective lifestyle modification...
Signifies the FDA’s recognition of the Company’s novel Cognitive Behavioral Therapy as a potential treatment for metabolic dysfunction-associated...
Agreement is an important step towards securing broad coverage Better Therapeutics Inc. (NASDAQ: BTTX), a pioneer in developing prescription...
Over a lifetime horizon AspyreRx plus standard of care (SoC) was estimated to be superior to SoC alone providing more life years and improvements...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.